Skip to content

Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France

Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03953690
Acronym
e-LUPUS
Enrollment
221
Registered
2019-05-16
Start date
2020-03-19
Completion date
2022-12-05
Last updated
2023-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus

Brief summary

Systemic lupus erythematosus (SLE) is a complex disease whose evaluation in daily practice and clinical research requires consideration of several aspects, in particular disease activity and quality of life. Health systems are increasingly using Patient Reported Outcome measures (PRO) data to measure different dimensions of the disease and its experience. In addition, there is a growing number of e-health tools for patients. Indeed, the collection of health-related data via an electronic system makes it possible to modernise and facilitate communication between patients and doctors within the framework of medical follow-up and therapeutic education. Nevertheless, very few studies measure the acceptability and effective long-term use of such tools, particularly in the context of SLE. The Sanoïa patient platform is a digital tool already used in therapeutic areas similar to SLE (discoid lupus erythematosus and rheumatoid arthritis), offering a guarantee of safety and a reduced individual cost. The availability of this health-related quality of life data collection tool via a site and a mobile application adapted to patients with SLE should: * Facilitate the collection by patients of their quality of life as part of their routine follow-up (patient access) * Limit the impact of patients' clinical profiles on the frequency of the collection of quality of life data * Enable internal medicine specialists to systematically use their patients' quality of life data during consultation (physician access). This study therefore proposes to evaluate this digital platform within the framework of SLE by measuring the distribution of access by physicians according to the data reported by patients and according to the characteristics of the facilities where the subjects were recruited for the study. These data will allow us to evaluate the influence of factors extrinsic to patients on the adoption of the tool. This area has been very poorly evaluated in the few studies that have focused on the adoption of such tools.

Interventions

OTHERuse of e-Health service

use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult \> 18 years old * Having given oral consent for participation * Confirmed systemic lupus diagnosis (ACR criteria) * Regular follow-up in the centre for more than 12 months * With Internet access at home * Affiliated with national health insurance system or other system

Exclusion criteria

* Persons subject to a legal protection measure (curatorship, guardianship) * Persons subject to limited judicial protection * Adults who are incapable or unable to express their consent * Patients who cannot read French * Patients whose cognitive status does not allow them to track their health data on a digital platform * Patients to be followed up in another centre within 12 months

Design outcomes

Primary

MeasureTime frameDescription
utilization rate of online patient accountThrough study completion, an average of 24 monthsrate of use of the patient account at least twice, at least 1 month apart, over a 12-month period

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026